Hypoxia response element-driven cytosine deaminase/5-fluorocytosine gene therapy system: A highly effective approach to overcome the dynamics of tumour hypoxia and enhance the radiosensitivity of prostate cancer cells in vitro

Journal of Gene Medicine

Volumn 11, Issue 2, 2009, Pages 169-179

  Marignol, Laure ^a   Foley, Ruth ^a   Southgate, Thomas D ^b   Coffey, Mary ^a   Hollywood, Donal ^a   Lawler, Mark ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

Gene therapy; Hypoxia; Prostate; Radiation

Indexed keywords

CYTOSINE DEAMINASE; FLUCYTOSINE; FLUOROURACIL; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; VASCULOTROPIN;

ARTICLE; CANCER CELL; CANCER GENE THERAPY; CONTROLLED STUDY; GENE TARGETING; GENE VECTOR; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HYPOXIA; IN VITRO STUDY; IONIZING RADIATION; PRIORITY JOURNAL; PROSTATE CANCER; RADIOSENSITIVITY; REOXYGENATION; SUICIDE GENE THERAPY; CELL HYPOXIA; CELL SURVIVAL; DNA RESPONSIVE ELEMENT; GENE THERAPY; GENETICS; MALE; METABOLISM; METHODOLOGY; PROSTATE TUMOR; RADIATION DOSE; TUMOR CELL LINE;

CELL HYPOXIA; CELL LINE, TUMOR; CELL SURVIVAL; CYTOSINE DEAMINASE; FLUCYTOSINE; GENE THERAPY; GENETIC VECTORS; HUMANS; MALE; PROSTATIC NEOPLASMS; RADIATION TOLERANCE; RESPONSE ELEMENTS; TRANSFECTION;

EID: 62249133803     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1281     Document Type: Article

References (56)

1. Mangar SA, Huddart RA, Parker CC, et al. Technological advances in radiotherapy for the treatment of localised prostate cancer. Eur J Cancer 2005; 41: 908-921.
2. Potters L, Torre T, Fearn PA, et al. Potency after permanent prostate brachytherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2001; 50: 1235-1242.
3. Machtens S, Baumann R, Hagemann J, et al. Long-term results of interstitial brachytherapy (LDR-Brachytherapy) in the treatment of patients with prostate cancer. World J Urol 2006; 24: 289-295.
4. Zelefsky MJ, Chan H, Hunt M, et al. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol 2006; 176: 1415-1419.
5. Lagerveld BW, Laguna MP, de la Rosette JJ. Long-term results after external beam radiation therapy for T1-T2 localized prostate cancer. Curr Urol Rep 2003; 4: 240-247.
6. Dasu A. Is the alpha/beta value for prostate tumours low enough to be safely used in clinical trials? Clin Oncol (RColl Radiol) 2007; 19: 289-301.
7. Movsas B, Chapman JD, Greenberg RE, et al. Increasing levels of hypoxia in prostate carcinoma correlate significantly with increasing clinical stage and patient age: an Eppendorf pO(2) study. Cancer 2000; 89: 2018-2024.
8. Nahum AE, Movsas B, Horwitz EM, et al. Incorporating clinical measurements of hypoxia into tumor local control modeling of prostate cancer: implications for the alpha/beta ratio. Int J Radiat Oncol Biol Phys 2003; 57: 391-401.
9. Movsas B, Chapman JD, Horwitz EM, et al. Hypoxic regions exist in human prostate carcinoma. Urology 1999; 53: 11-8.
10. Movsas B, Chapman JD, Hanlon AL, et al. Hypoxic prostate/muscle pO2 ratio predicts for biochemical failure in patients with prostate cancer: preliminary findings. Urology 2002; 60: 634-639.
11. Zhong H, De Marzo AM, Laughner E, et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 1999; 59: 5830-5835.
12. Lekas A, Lazaris AC, Deliveliotis C, et al. The expression of hypoxia-inducible factor-1alpha (HIF-1alpha) and angiogenesis markers in hyperplastic and malignant prostate tissue. Anticancer Res 2006; 26: 2989-2993.
13. Zhong H, Hanrahan C, van der Poel H, et al. Hypoxia-inducible factor 1alpha and 1beta proteins share common signaling pathways in human prostate cancer cells. Biochem Biophys Res Commun 2001; 284: 352-356.
14. Blancher C, Harris AL. The molecular basis of the hypoxia response pathway: tumour hypoxia as a therapy target. Cancer Metastasis Rev 1998; 17: 187-194.
15. Milosevic M, Chung P, Parker C, et al. Androgen withdrawal in patients reduces prostate cancer hypoxia: implications for disease progression and radiation response. Cancer Res 2007; 67: 6022-6025.
16. Lee AK. Radiation therapy combined with hormone therapy for prostate cancer. Semin Radiat Oncol 2006; 16: 20-28.
17. Horii K, Suzuki Y, Kondo Y, et al. Androgen-dependent gene expression of prostate-specific antigen is enhanced synergistically by hypoxia in human prostate cancer cells. Mol Cancer Res 2007; 5: 383-391.
18. Park SY, Kim YJ, Gao AC, et al. Hypoxia increases androgen receptor activity in prostate cancer cells. Cancer Res 2006; 66: 5121-9.
19. Melillo G. Inhibiting hypoxia-inducible factor 1 for cancer therapy. Mol Cancer Res 2006; 4: 601-605.
20. Jiang BH, Rue E, Wang GL, et al. Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. J Biol Chem 1996; 271: 17771-17778.
21. Eliceiri BP, Paul R, Schwartzberg PL, et al. Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Mol Cell 1999; 4: 915-924.
22. Alvarez-Tejado M, Naranjo-Suarez S, Jimenez C, et al. Hypoxia induces the activation of the phosphatidylinositol 3-kinase/Akt cell survival pathway in PC12 cells: protective role in apoptosis. J Biol Chem 2001; 276: 22368-22374.
23. Chun YS, Lee KH, Choi E, et al. Phorbol ester stimulates the nonhypoxic induction of a novel hypoxia-inducible factor 1alpha isoform: implications for tumor promotion. Cancer Res 2003; 63: 8700-8707.
24. Zhong XS, Zheng JZ, Reed E, et al. SU5416 inhibited VEGF and HIF-1alpha expression through the PI3K/AKT/p70S6K1 signaling pathway. Biochem Biophys Res Commun 2004; 324: 471-480.
25. Marignol L, Lawler M, Coffey M, et al. Achieving hypoxiainducible gene expression in tumors. Cancer Biol Ther 2005; 4: 359-364.
26. Austin EA, Huber BE. A first step in the development of gene therapy for colorectal carcinoma: cloning, sequencing, and expression of Escherichia coli cytosine deaminase. Mol Pharmacol 1993; 43: 380-387.
27. Freytag SO, Stricker H, Peabody J, et al. Five-year follow-up of trial of replication-competent adenovirus-mediated suicide gene therapy for treatment of prostate cancer. Mol Ther 2007; 15: 636-642.
28. Barton KN, Paielli D, Zhang Y, et al. Second-generation replication-competent oncolytic adenovirus armed with improved suicide genes and ADP gene demonstrates greater efficacy without increased toxicity. Mol Ther 2006; 13: 347-356.
29. Ireton GC, McDermott G, Black ME, et al. The structure of Escherichia coli cytosine deaminase. J Mol Biol 2002; 315: 687-697.
30. Shibata T, Akiyama N, Noda M, et al. Enhancement of gene expression under hypoxic conditions using fragments of the human vascular endothelial growth factor and the erythropoietin genes. Int J Radiat Oncol Biol Phys 1998; 42: 913-916.
31. Shibata T, Giaccia AJ, Brown JM. Development of a hypoxia-responsive vector for tumor-specific gene therapy. Gene Ther 2000; 7: 493-498.
32. Lu S, Gu X, Hoestje S, et al. Identification of an additional hypoxia responsive element in the glyceraldehyde-3-phosphate dehydrogenase gene promoter. Biochim Biophys Acta 2002; 1574: 152-156.
33. Bromfield GP, Meng A, Warde P, et al. Cell death in irradiated prostate epithelial cells: role of apoptotic and clonogenic cell kill. Prostate Cancer Prostatic Dis 2003; 6: 73-85.
34. Shoemaker RH. The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 2006; 6: 813-823.
35. Zolzer F, Streffer C. Increased radiosensitivity with chronic hypoxia in four human tumor cell lines. Int J Radiat Oncol Biol Phys 2002; 54: 910-920.
36. Corban-Wilhelm H, Ehemann V, Becker G, et al. Comparison of different methods to assess the cytotoxic effects of cytosine deaminase and thymidine kinase gene therapy. Cancer Gene Ther 2004; 11: 208-214.
37. McKeown SR, Cowen RL, Williams KJ. Bioreductive drugs: from concept to clinic. Clin Oncol (R Coll Radiol) 2007; 19: 427-442.
38. Chadderton N, Cowen RL, Sheppard FC, et al. Dual responsive promoters to target therapeutic gene expression to radiation-resistant hypoxic tumor cells. Int J Radiat Oncol Biol Phys 2005; 62: 213-222.
39. Greco O, Marples B, Dachs GU, et al. Novel chimeric gene promoters responsive to hypoxia and ionizing radiation. Gene Ther 2002; 9: 1403-1411.
40. Jones B, Dale RG. Estimation of tumour hypoxic fraction from clinical data sets compatible with accelerated repopulation. Acta Oncol 1998; 37: 263-268.
41. Ruggieri R. Hypofractionation in non-small cell lung cancer (NSCLC): suggestions from modelling both acute and chronic hypoxia. Phys Med Biol 2004; 49: 4811-4823.
42. Dachs GU, Patterson AV, Firth JD, et al. Targeting gene expression to hypoxic tumor cells. Nat Med 1997; 3: 515-20.
43. Ruan H, Su H, Hu L, et al. A hypoxia-regulated adeno-associated virus vector for cancer-specific gene therapy. Neoplasia 2001; 3: 255-263.
44. Dewhirst MW. Intermittent hypoxia furthers the rationale for hypoxia-inducible factor-1 targeting. Cancer Res 2007; 67: 854-855.
45. Martinive P, Defresne F, Bouzin C, et al. Preconditioning of the tumor vasculature and tumor cells by intermittent hypoxia: implications for anticancer therapies. Cancer Res 2006; 66: 11736-11744.
46. Coffey RN, Morrissey C, Taylor CT, et al. Resistance to caspase-dependent, hypoxia-induced apoptosis is not hypoxia-inducible factor-1 alpha mediated in prostate carcinoma cells. Cancer 2005; 103: 1363-1374.
47. Cardenas-Navia LI, Yu D, Braun RD, et al. Tumor-dependent kinetics of partial pressure of oxygen fluctuations during air and oxygen breathing. Cancer Res 2004; 64: 6010-6017.
48. Chaplin DJ, Hill SA. Temporal heterogeneity in microregional erythrocyte flux in experimental solid tumours. Br J Cancer 1995; 71: 1210-1213.
49. Ehrnrooth E, von der Maase H, Sorensen BS, et al. The ability of hypoxia to modify the gene expression of thymidylate synthase in tumour cells in vivo. Int J Radiat Biol 1999; 75: 885-891.
50. Fischer U, Steffens S, Frank S, et al. Mechanisms of thymidine kinase/ganciclovir and cytosine deaminase/5-fluorocytosine suicide gene therapy-induced cell death in glioma cells. Oncogene 2005; 24: 1231-1243.
51. Pandha HS, Martin LA, Rigg A, et al. Genetic prodrug activation therapy for breast cancer: A phase I clinical trial of erbB- 2-directed suicide gene expression. J Clin Oncol 1999; 17: 2180-2189.
52. Wang JZ, Li XA, Mayr NA. Dose escalation to combat hypoxia in prostate cancer: a radiobiological study on clinical data. Br J Radiol 2006; 79: 905-911.
53. Torres-Roca JF. The role of external-beam radiation therapy in the treatment of clinically localized prostate cancer. Cancer Control 2006; 13: 188-193.
54. Lee CB, Stinchcombe TE, Rosenman JG, et al. Therapeutic advances in local-regional therapy for stage III non-small-cell lung cancer: evolving role of dose-escalated conformal (3- dimensional) radiation therapy. Clin Lung Cancer 2006; 8: 195-202.
55. Stevens CW, Zeng M, Cerniglia GJ. Ionizing radiation greatly improves gene transfer efficiency in mammalian cells. Hum Gene Ther 1996; 7: 1727-1734.
56. Freytag SO, Stricker H, Movsas B, et al. Prostate cancer gene therapy clinical trials. Mol Ther 2007; 15: 1042-1052.